DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for anaplastic oligodendroglioma — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAnaplastic oligodendroglioma maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for anaplastic oligodendroglioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
In 1990, three patients with newly diagnosed aggressive oligodendroglioma were given PCV-3 chemotherapy before radiotherapy. All three had residual or progressive tumour after initial surgery. The authors concluded that chemotherapy for response induction followed by radiotherapy for consolidation was feasible and effective initial treatment, but the series was small.
A 1991 commentary noted that conventional experience held high-grade gliomas to be unresponsive to chemotherapy, but acknowledged that Cairncross and Macdonald had found anaplastic oligodendroglioma to be chemoresponsive. The commentary stated the results were impressive but the series was small, and questions remained about subtypes, dose, and the best chemotherapeutic combination.
In 2001, 30 patients with recurrent anaplastic oligodendroglioma were given temozolomide orally at 150 to 200 mg/m2 on days 1 through 5 of 28-day cycles. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy, and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. The authors noted that patients not responding to PCV might respond to temozolomide.
What is still missing is evidence from larger, randomised trials that stratify patients by prior treatment and molecular subtype. No trial has yet established a standard sequence or combination that improves overall survival in a definitive manner, and funding for such trials remains limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Neurology · 1990 · 137 citations
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
AbstractWe treated 3 patients with newly diagnosed aggressive oligodendroglioma with chemotherapy prior to radiotherapy and observed responses. All had residual or progressive tumor following initial surgery. We used a combination called PCV-3 because recurrent anaplastic oligodendroglioma responds predictably to this regimen. Chemotherapy for response induction followed by radiotherapy for consolidation is feasible and effective initial treatment for this tumor.
Temozolomide chemotherapy in recurrent oligodendroglioma
AbstractThe authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.
AbstractConventional experience suggests that high-grade gliomas do not respond to chemotherapy. However, Cairncross and Macdonald have found anaplastic oligodendroglioma to be chemoresponsive. Their results are impressive, but their series is small. While questions remain about subtypes, dose, and the best chemotherapeutic combination, it is already clear that at least some anaplastic oligodendrogliomas are chemosensitive.—
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
